Skip to main content
PCRX
NASDAQ Life Sciences

Pacira Discloses Two Merger Suits and 15 Demand Letters Over 14D-9 Disclosures

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$36.46
Mkt Cap
$1.462B
52W Low
$18.8
52W High
$36.665
52W Position info
94% above low
Off High info
at 52W high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

PCRX sits 94% above its 52-week low of $18.8.

Summary

Pacira disclosed two New York state court suits and fifteen demand letters alleging its 14D-9 omitted material information about the $36.50-per-share Viatris merger. The plaintiffs seek to block the deal or win damages; Pacira says the disclosures comply with law.


Key Events · Legal and Risk Events · PCRX

  • Two Merger Suits Filed

    Carroll v. Pacira (Index No. 656215/2026) and Burke v. Pacira (Index No. 656243/2026) were filed in New York Supreme Court, naming Pacira and each board member as defendants.

  • Claims and Relief Sought

    Plaintiffs allege negligent misrepresentation and concealment over the Schedule 14D-9 and seek to enjoin the deal until omitted information is disclosed, or rescission and damages if it closes.

  • Fifteen Demand Letters Received

    Pacira has received fifteen demand letters, including two draft complaints, generally seeking disclosure of information allegedly omitted from the Schedule 14D-9.

  • No Service, No Loss Estimate

    The Pacira Defendants have not been served and say they cannot predict the outcome or estimate a possible loss range; they intend to defend the disclosures.


Analysis · PCRX · Life Sciences

Two stockholder suits and fifteen demand letters now challenge the disclosure in Pacira's Schedule 14D-9 for the $36.50-per-share Viatris tender offer. The complaints seek to block the deal until more information is disclosed, or rescission and damages if it closes. Pacira says it will defend the disclosures and cannot estimate a loss range. This is standard merger-objection litigation, but it can delay the tender closing and adds legal cost; the company has not been served yet.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PCRX was trading at $36.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.80 to $36.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PCRX - Latest Insights

PCRX
Nov 05, 2026, 4:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $36.42
Real-time Price: $36.46 info
Change: +$0.040 (+0.11%) info
Market Cap: $1.462B info
PCRX
Nov 05, 2026, 4:33 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.42
Real-time Price: $36.46 info
Change: +$0.040 (+0.11%) info
Market Cap: $1.462B info
PCRX
Oct 30, 2026, 8:32 AM EDT
Filing Type: SC 14D9
Importance Score:
8
Price at Filing: $36.35
Real-time Price: $36.46 info
Change: +$0.110 (+0.30%) info
Market Cap: $1.462B info
PCRX
Oct 13, 2026, 5:54 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $36.38
Real-time Price: $36.46 info
Change: +$0.080 (+0.22%) info
Market Cap: $1.462B info
PCRX
Oct 08, 2026, 9:24 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $36.34
Real-time Price: $36.46 info
Change: +$0.120 (+0.33%) info
Market Cap: $1.462B info